Product image of Mycophenolate Hexal (Mycophenolate Mofetil) supplied by GNH India

Mycophenolate Hexal

Active Ingredient:
Mycophenolate Mofetil
Origin:
EU

Mycophenolate Hexal (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycophenolate Hexal, is an antimetabolite presented as an oral tablet for oral use. It is employed to prevent organ transplant rejection and to treat certain autoimmune diseases such as lupus nephritis and vasculitis.
GNH India supplies Mycophenolate Hexal as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Hexal Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mycophenolate Hexal is used to suppress immune activity in transplant and autoimmune disease settings.

  • Organ transplant rejection prevention: reduces the risk of acute and chronic graft rejection by inhibiting lymphocyte proliferation.
  • Lupus nephritis: helps control renal inflammation and preserve kidney function in systemic lupus erythematosus.
  • Vasculitis: contributes to disease control by limiting immune‑mediated vessel inflammation.

How It Works

  • Mycophenolate Mofetil is converted intracellularly to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). This enzyme is essential for de novo synthesis of guanosine nucleotides in lymphocytes. By limiting guanosine availability, the drug suppresses proliferation of T and B cells, thereby reducing immune responses involved in graft rejection and autoimmune inflammation.

Side Effects

Mycophenolate Hexal may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal pain.
  • Hematologic changes: anemia, leukopenia, or thrombocytopenia.
  • Infections: increased susceptibility to bacterial, viral, or fungal infections.
  • Headache: mild to moderate intensity.

Serious or Rare Side Effects

  • Severe infection: opportunistic infections such as Pneumocystis jirovecii pneumonia.
  • Progressive multifocal leukoencephalopathy (PML): rare demyelinating brain disease.
  • Malignancy: increased risk of lymphoproliferative disorders or skin cancers.
  • Pregnancy complications: fetal toxicity and miscarriage.

Precautions & Warnings

Before prescribing Mycophenolate Hexal, clinicians should consider several safety precautions.

  • Pregnancy risk: category D, avoid use during pregnancy unless benefits outweigh risks.
  • Breastfeeding: contraindicated, as drug is excreted in milk.
  • Renal impairment: adjust dose and monitor renal function.
  • Hepatic impairment: use with caution and monitor liver enzymes.
  • Infection monitoring: screen for latent infections and monitor for new infections.
  • Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Avoid Interactions

Mycophenolate Hexal can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Antacids containing aluminum or magnesium: reduce absorption of mycophenolic acid.
  • Azathioprine: additive bone marrow suppression.
  • Live vaccines: increased risk of infection.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase mycophenolate levels.
  • CYP3A4 inducers (e.g., rifampin, carbamazepine): decrease drug exposure.
  • Non‑live vaccines: may have reduced efficacy, monitor immune response.

Frequently Asked Questions

Mycophenolate Hexal is prescribed to prevent rejection of transplanted organs and to treat certain autoimmune disorders, including lupus nephritis and vasculitis, by dampening the body’s immune response.

The drug is converted to mycophenolic acid, which selectively blocks inosine monophosphate dehydrogenase (IMPDH). This inhibition curtails guanosine nucleotide synthesis, limiting proliferation of T and B lymphocytes and thereby suppressing immune activity.

The appropriate dose is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and other individual factors. No fixed regimen is provided here.

Mycophenolate Hexal is classified as pregnancy category D, indicating evidence of fetal risk. It should be avoided during pregnancy and breastfeeding unless the potential benefit justifies the risk, and alternative therapies are considered.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine, Mycophenolate Hexal offers a different mechanism—targeting nucleotide synthesis rather than calcineurin signaling. It is often used in combination regimens to achieve synergistic immunosuppression while potentially reducing dose‑related toxicity of each agent.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging to protect from moisture and light, and ensure the container is tightly closed when not in use.

Mycophenolate Hexal is taken orally, usually with food or a glass of water to improve tolerability. The exact administration schedule—once or twice daily—depends on the prescriber’s instructions.

Serious concerns include opportunistic infections, progressive multifocal leukoencephalopathy (PML), severe bone‑marrow suppression leading to anemia or leukopenia, and potential fetal toxicity if pregnancy occurs during treatment.

Patients with known hypersensitivity to mycophenolate mofetil or any component of the formulation, pregnant or breastfeeding women, and individuals with uncontrolled severe infections should avoid using Mycophenolate Hexal unless a specialist advises otherwise.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolate Mofetil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT